<DOC>
	<DOC>NCT00601068</DOC>
	<brief_summary>In cooperation with Merck &amp; Co, Inc. we will identify and form a database of 35 patients who have developed osteochemonecrosis of the jaws related to oral bisphosphonate use. We will study the triggers, associated medical conditions and medications, location of the lesion(s), and patient outcomes.</brief_summary>
	<brief_title>Proposal For The Development Of A Well Defined Database For Patients With Oral Bisphosphonate-Related Osteonecrosis</brief_title>
	<detailed_description>This study is an observational study, and not a comparative trial. The major outcome is represented by the fraction of subjects with long term healed lesions.</detailed_description>
	<mesh_term>Osteonecrosis</mesh_term>
	<mesh_term>Bisphosphonate-Associated Osteonecrosis of the Jaw</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Exposed bone in the oral cavity of greater than 68 weeks duration unresponsive to therapy Pregnant patients Patients less than 30 yrs of age or greater than 90 yrs of age Mentally incompetent individuals</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>osteonecrosis, jaws, bisphosphonate, fosamax, alendronate</keyword>
</DOC>